BPC-157 is a 15-amino-acid peptide derived from human gastric juice that has been studied for two decades in animal models — and is now at the center of a fast-changing 2026 U.S. regulatory story. This article covers what the peptide is, the salt forms (acetate vs arginate), the reconstitution math in insulin-syringe units, the published dosing literature, and the current regulatory picture: 2023 FDA Category 2 placement, the February 2026 HHS reclassification signal, the upcoming July 2026 PCAC review, and BPC-157's standing on the WADA Prohibited List.
This is an educational pharmacology overview, not a recommendation to use BPC-157. BPC-157 is not an FDA-approved drug for any human indication. Adequately powered human clinical trials are still lacking. Talk to a qualified clinician about anything you put in your body.
BPC-157 — body protective compound 157 — is a pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It was first characterized by the Sikiric group at the University of Zagreb as the essential active fragment of a larger BPC peptide isolated from human gastric juice. Twenty-plus years of preclinical work has examined its effects on gastrointestinal tract injury, musculoskeletal healing (tendon, ligament, muscle), vascular function (angiogenesis, NO signaling), and the central nervous system. The mechanistic picture is broad and not fully consolidated; the most-cited recent reviews are the 2025 MDPI Pharmaceuticals literature and patent review (Józwiak et al.) and the 2025 narrative review on musculoskeletal healing (PMC12446177).
Critically, almost all data are preclinical (rodent, rabbit, dog). Human evidence is limited to a small number of pilot studies — see the regulatory section below.
Lyophilized BPC-157 is sold (for research use) as either an acetate or arginate salt. Both contain the same active pentadecapeptide; the difference is the counter-ion paired with the peptide:
Manufacturer-published stability claims for arginate (e.g., 96% potency at 18 months refrigerated) come from supplier data, not peer-reviewed studies — treat them as directional. Both forms behave identically once in plasma, because the counter-ion dissociates immediately on dilution.
Reconstitution math for BPC-157 is the same as for any lyophilized peptide. We covered the full derivation in How to Calculate Peptide Reconstitution: Insulin Syringe Units Explained. Quick-reference for a typical 5 mg vial:
| Vial | BAC water added | Concentration | µg per insulin unit | Units for 250 µg |
|---|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL (5,000 µg/mL) | 50 µg | 5 units |
| 5 mg | 2 mL | 2.5 mg/mL (2,500 µg/mL) | 25 µg | 10 units |
| 5 mg | 5 mL | 1 mg/mL (1,000 µg/mL) | 10 µg | 25 units |
| 10 mg | 2 mL | 5 mg/mL (5,000 µg/mL) | 50 µg | 5 units |
The math: concentration (mg/mL) = vial mass / BAC water volume; µg per unit = concentration (µg/mL) ÷ 100 (because a 100-unit insulin syringe maps 100 units to 1 mL); units for desired dose = µg ÷ µg-per-unit. Choose the BAC water volume that puts your most common dose in the 5–25 unit range — that's the sweet spot for syringe accuracy.
Animal studies use a wide dose range. The Sikiric 2019 review (PMID 30915550) summarizes effective doses from approximately 10 ng/kg to 10 µg/kg in rodents — a four-orders-of-magnitude range across which the Sikiric group consistently reports effects, often described as essentially dose-independent within that window.
That dose-independence is part of why human-equivalent translation is fraught. Naive scaling of the rodent µg/kg range to a 70-kg adult would yield extremely small absolute doses (microgram range), but rodent-to-human dose translation requires body-surface-area adjustment and human PK calibration that have not been done.
For human pharmacokinetics, the only published systematic data is in animals (Frontiers in Pharmacology 2022 — PK, distribution, metabolism, excretion in rats and dogs). Human PK has been examined only in one IV pilot, and is not in the public peer-reviewed literature in a form that supports clinical dosing.
This is the part most internet content elides. As of 2026, the human evidence base for BPC-157 consists of:
There are no completed adequately powered randomized controlled trials of BPC-157 for any indication. The 2025 narrative review (PMC12446177) explicitly notes the lack of RCTs in orthopaedic indications and concludes that confidence in efficacy or real-world side-effect profile cannot be established from the available evidence. This does not mean BPC-157 doesn't work — it means we don't have the data to say one way or the other.
The most-cited preclinical safety study is Xu et al. 2020 in Regulatory Toxicology and Pharmacology (PMID 32334036): single-dose and repeated-dose toxicity in mice, rats, rabbits, and dogs. The authors reported BPC-157 was well tolerated and could not identify a minimum toxic dose or a lethal dose. No genotoxicity, no embryo-fetal toxicity, no anaphylactic effects, mild local irritation only. This is a favorable preclinical safety record. It is not a substitute for human safety data, which does not exist at scale.
BPC-157's U.S. compounding status has changed materially in 2026. A timeline:
| Date | Event |
|---|---|
| 2023 | FDA places BPC-157 on the Category 2 list — bulk drug substances that "may present significant safety risks" and may not be used in 503A or 503B compounding pending further review. Stated FDA concerns: immunogenicity, peptide-related impurities, insufficient safety data. |
| Feb 27, 2026 | HHS Secretary Robert F. Kennedy Jr. publicly announces that approximately 14 of 19 peptides on the Category 2 list will be moved back toward compoundable status. |
| Spring 2026 | BPC-157 is removed from the active Category 2 list as the original nominations are withdrawn. The substance is not "approved" — it is no longer on the active do-not-compound list. |
| Jul 23–24, 2026 | FDA Pharmacy Compounding Advisory Committee (PCAC) meeting: BPC-157 (free base) and BPC-157 acetate are on the agenda for consideration for inclusion on the 503A bulks list. The committee's recommendation, and FDA's response, will determine the formal compounding pathway. |
The plain-English summary: as of mid-2026, BPC-157 sits in regulatory limbo. It is not on the active "do not compound" list, but it is also not on the formal 503A bulks list. The PCAC review in late July 2026 is the next inflection point. Track the official FDA page on bulk drug substances of compounding concern for the authoritative current status.
Importantly: even if BPC-157 returns to the 503A bulks list, that authorizes compounding by licensed pharmacies under prescription — it does not make BPC-157 an FDA-approved drug. There is no approved indication, no labeled dose, no labeled safety profile.
BPC-157 has been on the WADA Prohibited List under category S0 (Non-Approved Substances) since January 2022. It is prohibited at all times — in-competition and out-of-competition — and detection in any sample triggers an Anti-Doping Rule Violation. The U.S. Anti-Doping Agency has published explicit guidance for athletes. If you compete in a sport that follows WADA — Olympic, NCAA, USADA-tested professional leagues — BPC-157 use is a sanctionable offense regardless of FDA status. The U.S. Department of Defense's Operation Supplement Safety has published parallel guidance for service members.
Dose Track supports BPC-157 in its peptide database with calibrated reconstitution math and dose logging. The app's reconstitution calculator handles the BAC-water-volume → mg/mL → insulin-units conversion automatically, and the dose log maintains a clean record of injection site, time, and amount — useful regardless of what protocol you and your clinician land on. For broader peptide context see peptide tracking features, reconstitution math, the supported medications list, or download on the App Store.